NCNP

Through joint research with the National Center of Neurology and Psychiatry (NCNP), Tokyo, and making practical use of our fundamental nucleic acid technologies developed at Discovery Research Laboratories in Tsukuba, we have developed an antisense nucleic acid drug, Viltepso^®(NS-065/NCNP-01), for the treatment of Duchenne muscular dystrophy.